Related Experiment Video
Updated: May 28, 2026

Using Nanoplasmon-Enhanced Scattering and Low-Magnification Microscope Imaging to Quantify Tumor-Derived Exosomes
Published on: May 24, 2019
Accurate Phenotyping at the Single-Exosome Level Using a Proximity-Ligation RCA-Based Light-Scattering Counting
Baoshui Zhang1, Pengbo Zhang1, Mou Li2
1Beijing Key Laboratory for Bioengineering and Sensing Technology, School of Chemistry and Biological Engineering, University of Science and Technology Beijing, 30 Xueyuan Road, Haidian District, Beijing 100083, China.
Abstract:
Tumor-derived exosomes (TEXs), carrying rich proteomic information, have shown great promise as noninvasive biomarkers for cancer detection. However, their inherent heterogeneity, relatively low abundance, and significant interference from non-TEXs in biological fluids pose considerable challenges for accurate and sensitive TEX quantification. To address this, we developed a highly sensitive and specific light-scattering counting platform based on proximity-ligation-mediated rolling circle amplification (RCA), enabling single-particle detection of exosomes. The approach employs dual aptamers that bind specifically to a single exosome, triggering proximity ligation and RCA. This process promotes the aggregation of small gold nanoparticles (AuNPs), generating a strong turn-on light-scattering signal from an initial near-zero background, which is then visualized as diffraction-limited spots. By using a single microbead as the signal enrichment platform to concentrate all exosome-derived signals, we achieved a detection sensitivity as low as 1 particle/μL. Furthermore, conjoint analysis of pairwise combinations of multiple exosomal proteins significantly improved diagnostic specificity, allowing precise discrimination between breast cancer patients and healthy individuals using just 1 μL of clinical plasma. By targeting other cancer-specific biomarkers, this platform can be readily adapted to detect other cancers, offering a versatile and scalable tool for early cancer diagnosis in the field of liquid biopsy.

